New Haven Pharmaceuticals to present Durlaza data at AHA conference

New Haven Pharmaceuticals said Monday that data on the antiplatelet effects of Durlaza will be presented in a poster session during the American Heart Association (AHA) Scientific Sessions that begin this weekend in Orlando, Florida.

Durlaza, approved by the Food and Drug Administration (FDA), is an extended-release aspirin capsule that aims to prevent heart attacks in individuals with chronic coronary artery disease and recurrent stroke in those who have experienced an ischemic stroke or transient ischemic attack. Durlaza is also intended to reduce risk of death for both situations.

Paul A. Gurbel, a cardiologist and director of the Center for Thrombosis Research at Sinai Hospital of Baltimore in Maryland, will lead the poster presentation at 9 a.m. Tuesday at the sessions, which run through Nov. 11. Gurbel and his team at Sinai have studied the role blood platelets have in the development of blood clots and coronary-related events. They have made strides in the field of personalized antiplatelet therapy which improves outcomes for patients.

“We are excited that coming on the heels of FDA approval for Durlaza that this study will be presented at the American Heart Association’s annual meeting," New Haven Pharmaceuticals CEO Patrick Fourteau said. "This presentation represents an important opportunity to share data and other details about Durlaza with the cardiovascular community."